Teva Pharma Industries Ltd ADR (TEVA)

Sep 25, 2026

A Delaware federal court has ruled that generic drugmakers Teva Pharmaceuticals and Apotex Inc. do not infringe patents held by Vanda Pharmaceuticals for its sleep drug Hetlioz. This decision allows Teva and Apotex to potentially market generic versions of the medication without facing patent infringement claims from Vanda. The ruling is a significant development in the pharmaceutical industry for these companies.

Sep 22, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) Director Roberto Mignone recently sold 367,600 shares of the company's stock for approximately $14.36 million at an average price of $39.06. This transaction occurred as Teva shares traded near their 52-week high, with the company reporting quarterly revenue of $4.14 billion and EPS of $0.02. Analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and an average price target of $43.10.

Sep 22, 2026

Teva Pharmaceutical Industries is undergoing a significant transformation, moving from a generics-focused company to a biopharmaceutical one. Under CEO Richard Francis, the company has cleaned up its balance sheet, quadrupled its stock value in five years, and is focusing on developing proprietary drugs for chronic diseases, with several promising candidates in advanced clinical trials. While the comeback is evident, the challenge remains to demonstrate sustained financial growth and secure FDA approvals for new drugs to fully realize its potential.

Sep 21, 2026

Nykredit A S has acquired a new stake in Teva Pharmaceutical Industries Ltd., purchasing 340,196 shares valued at $11.5 million during the second quarter. This move aligns with a largely positive analyst sentiment, with Teva maintaining a "Moderate Buy" consensus and an average price target of $43.10. The company is poised for growth due to positive real-world data for its neuroscience drugs UZEDY and TEV-'749, the latter awaiting FDA approval.

Sep 16, 2026

This report highlights unusual options volume for Forgent Power Solutions (FPS), Teva Pharmaceutical Industries (TEVA), and Aflac (AFL). FPS surged after strong Q4 results, seeing significant call option activity. TEVA experienced increased options trading as its primary shares transitioned to the NYSE, with calls outpacing puts. AFL showed heavy options activity, evenly split between calls and puts, despite news of Japan Post Holdings selling some of its shares.

Sep 15, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) recently hit a new 52-week high of $38.42, trading up 5.4% with a market capitalization of $45.57 billion. Analyst sentiment remains positive, with a consensus "Moderate Buy" rating and an average price target of $43.10. The company reported quarterly revenue of $4.14 billion and earnings of $0.02 per share, with institutional investors holding 54.05% of the stock.